Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Click here to view

Presentation

A Phase I/II Multicenter Gene Therapy Clinical Study for Fabry Disease

Download PDF